Unit Head: Edith Monteagudo [Ph.D.]

Our Preclinical Research team conducts both in vitro and in vivo studies, utilizing state-of-the-art technology to support the selection of compounds with appropriate ADME (absorption, distribution and metabolism) properties for further development as drug candidates.

IRBMWe have significant expertise in qualitative and quantitative analyses of small molecules, peptides and proteins in biological fluids and tissues, and our operations are supported by integrated and automated sample processing and analysis platforms which minimize human error and provide highly reproducible and accurate data, meeting the timelines required in drug discovery.

The Preclinical Research team supports all the DMPK assays normally used to profile compound candidates in hit-to lead and lead optimization space and generates ad hoc ones to meet project needs. Our team of experienced scientists creates innovative solutions for the identification of xenobiotic and endogenous metabolites from biological samples and of biomarkers using target or untargeted analysis.

The available, state-of-the-art mass spectrometry equipment (LC-MS/MS) allows for providing extreme sensitivity or flexibility depending on the goal.

Unit Capabilities

  • In vivo PK and metabolite ID studies for small molecules, peptides or other biologics;
  • Expertise in xenograft/PDX studies;
  • Metabolomics and biomarker ID in animal and human biofluids;
  • Formulation support;
  • State-of-the-art technology;
  • Flexible and fully automated workflow;
  • Extensive in-house validation expertise;
  • Fully equipped LAR;
  • Secure, easy data access.